1. Beighton P et al: Ehlers-Danlos syndromes: Revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet 77(1):31-37, 1998
2. Furukawa K, Okajima T: Galactosyltransferase I is a gene responsible for progeroid variant of Ehlers-Danlos syndrome: Molecular cloning and identification of mutations. Biochim Biophys Acta 1573(3):377-381, 2002
3. Beighton P: Hypermobility scoring. Br J Rheumatol 27(2):163, 1988
4. Lawrence EJ: The clinical presentation of Ehlers-Danlos syndrome. Adv Neonatal Care 5(6):301-314, 2005
5. Wenstrup RJ et al: COL5A1 haploinsufficiency is a common molecular mechanism underlying the classical form of EDS. Am J Hum Genet 66(6):1766-1776, 2000
6. Symoens S et al: COL5A1 signal peptide mutations interfere with protein secretion and cause classic Ehlers-Danlos syndrome. Hum Mutat 30(2):E395-E403, 2009
7. Wenstrup RJ et al: A splice-junction mutation in the region of COL5A1 that codes for the carboxyl propeptide of pro alpha 1(V) chains results in the gravis form of the Ehlers-Danlos syndrome (type I). Hum Mol Genet 5(11):1733-1736, 1996
8. Greenspan DS et al: COL5A1: Fine genetic mapping and exclusion as candidate gene in families with nail-patella syndrome, tuberous sclerosis 1, hereditary hemorrhagic telangiectasia, and Ehlers-Danlos Syndrome type II. Genomics 25(3):737-739, 1995
9. Nuytinck L et al: Classical Ehlers-Danlos syndrome caused by a mutation in type I
collagen.
Am J Hum Genet 66(4):1398-1402, 2000
10. Malfait F et al: Three
arginine to
cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood.
Hum Mutat 28(4):387-395, 2007
11. Schwarze U et al: Rare autosomal recessive cardiac valvular form of Ehlers-Danlos syndrome results from mutations in the COL1A2 gene that activate the nonsense-mediated RNA decay pathway. Am J Hum Genet 74(5):917-930, 2004
12. Burch GH et al: Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. Nat Genet 17(1):104-108, 1997
13. Mao JR, Bristow J: The Ehlers-Danlos syndrome: on beyond collagens. J Clin Invest 107(9):1063-1069, 2001
14. Hausser I, Anton-Lamprecht I: Differential ultrastructural aberrations of
collagen fibrils in Ehlers-Danlos syndrome types I-IV as a means of diagnostics and classification.
Hum Genet 93(4):394-407, 1994
15. Grahame R, Beighton P: Physical properties of the skin in the Ehlers-Danlos syndrome. Ann Rheum Dis 28(3):246-251, 1969
16. Tiller GE et al: Aortic root dilatation in Ehlers-Danlos syndrome types I, II and III. A report of five cases. Clin Genet 53(6):460-465, 1998
17. Machet L et al: Absence of inferior labial and lingual frenula in ehlers-danlos syndrome: A minor diagnostic criterion in French patients. Am J Clin Dermatol 11(4):269-273, 2010
18. Pepin M et al: Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 342(10):673-680, 2000
19. Wenstrup R, De PA: Ehlers-Danlos syndrome, classic type. In: GeneReviews at GeneTests: Medical Genetics Information Resource. Seattle, University of Washington, 1993,
http://www.genetests.org20. Snyder RR, Gilstrap LC, Hauth JC: Ehlers-Danlos syndrome and pregnancy. Obstet Gynecol 61(5):649-650, 1983
21. Ramos-E-Silva M et al: Connective tissue diseases: Pseudoxanthoma elasticum, anetoderma, and Ehlers-Danlos syndrome in pregnancy. Clin Dermatol 24(2):91-96, 2006
22. Wenstrup RJ et al: Prevalence of aortic root dilation in the Ehlers-Danlos syndrome. Genet Med 4(3):112-117, 2002
23. Narcisi P et al: A family with Ehlers-Danlos syndrome type III/articular hypermobility syndrome has a glycine 637 to serine substitution in type III
collagen.
Hum Mol Genet 3(9):1617-1620, 1994
24. Zweers MC et al: Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome. Am J Hum Genet 73(1):214-217, 2003
25. Callewaert B et al: Ehlers-Danlos syndromes and Marfan syndrome. Best Pract Res Clin Rheumatol 22(1):165-189, 2008
26. Chen W et al: The phenotypic spectrum of contiguous deletion of CYP21A2 and tenascin XB: Quadricuspid aortic valve and other midline defects. Am J Med Genet A 149A(12):2803-2808, 2009
27. Grahame R: Heritable disorders of connective tissue. Baillieres Best Pract Res Clin Rheumatol 14(2):345-361, 2000
28. Harinstein D et al: Systemic joint laxity (the hypermobile joint syndrome) is associated with temporomandibular joint dysfunction. Arthritis Rheum 31(10):1259-1264, 1988
29. Stoler JM, Oaklander AL: Patients with Ehlers Danlos syndrome and CRPS: A possible association? Pain 123(1-2):204-209, 2006
30. Lumley MA et al: Psychosocial functioning in the Ehlers-Danlos syndrome. Am J Med Genet 53(2):149-152, 1994
31. Levy HP. Ehlers-Danlos syndrome, hypermobility type. In: GeneReviews at GeneTests: Medical Genetics Information Resource. Seattle, University of Washington, 1993,
http://www.genetests.org32. Kobayasi T: Dermal elastic fibres in the inherited hypermobile disorders. J Dermatol Sci 41(3):175-185, 2006
33. McDonnell NB et al: Echocardiographic findings in classical and hypermobile Ehlers-Danlos syndromes. Am J Med Genet A 140(2):129-136, 2006
34. Castori M et al: Natural history and manifestations of the hypermobility type Ehlers-Danlos syndrome: A pilot study on 21 patients. Am J Med Genet A 152A(3):556-564, 2010
35. Cole WG et al: A base substitution at a splice site in the COL3A1 gene causes exon skipping and generates abnormal type III procollagen in a patient with Ehlers-Danlos syndrome type IV. J Biol Chem 265(28):17070-17077, 1990
36. Germain DP: Clinical and genetic features of vascular Ehlers-Danlos syndrome. Ann Vasc Surg 16(3):391-397, 2002
37. Pinnell SR et al: A heritable disorder of connective tissue. Hydroxylysine-deficient
collagen disease.
N Engl J Med 286(19):1013-1020, 1972
38. Eyre DR, Glimcher MJ: Reducible crosslinks in hydroxylysine-deficient collagens of a heritable disorder of connective tissue. Proc Natl Acad Sci U S A 69(9):2594-2598, 1972
39. Heikkinen J et al: Duplication of seven exons in the lysyl hydroxylase gene is associated with longer forms of a repetitive sequence within the gene and is a common cause for the type VI variant of Ehlers-Danlos syndrome. Am J Hum Genet 60(1):48-56, 1997
40. Ogur G et al: Clinical, ultrastructural and biochemical studies in two sibs with Ehlers-Danlos syndrome type VI-B-like features. Clin Genet 46(6):417-422, 1994
41. Pasquali M et al: Urinary pyridinium cross-links: A noninvasive diagnostic test for Ehlers-Danlos syndrome type VI. N Engl J Med 331(2):132-133, 1994
42. Eyre D et al: The kyphoscoliotic type of Ehlers-Danlos syndrome (type VI): Differential effects on the hydroxylation of lysine in collagens I and II revealed by analysis of cross-linked telopeptides from urine. Mol Genet Metab 76(3):211-216, 2002
43. Giunta C et al: The arthrochalasia type of Ehlers-Danlos syndrome (EDS VIIA and VIIB): The diagnostic value of
collagen fibril ultrastructure.
Am J Med Genet A 146A(10):1341-1346, 2008
44. Byers PH et al: Ehlers-Danlos syndrome type VIIA and VIIB result from splice-junction mutations or genomic deletions that involve exon 6 in the COL1A1 and COL1A2 genes of type I
collagen.
Am J Med Genet 72(1):94-105, 1997
45. Ho KK et al: Further evidence that the failure to cleave the aminopropeptide of type I procollagen is the cause of Ehlers-Danlos syndrome type VII. Hum Mutat 3(4):358-364, 1994
46. Nicholls
AC et al: Clinical phenotypes and molecular characterisation of three patients with Ehlers-Danlos syndrome type VII.
J Med Genet 37(11):E33, 2000
47. Giunta C et al: Ehlers-Danlos syndrome type VII: Clinical features and molecular defects. J Bone Joint Surg Am 81(2):225-238, 1999
48. Lehmann HW et al: Ehlers-Danlos syndrome type VII: Phenotype and genotype. Arch Dermatol Res 286(8):425-428, 1994
49. Colige A et al: Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene. Am J Hum Genet 65(2):308-317, 1999
50. Colige A et al: Novel types of mutation responsible for the dermatosparactic type of Ehlers-Danlos syndrome (Type VIIC) and common polymorphisms in the ADAMTS2 gene. J Invest Dermatol 123(4):656-663, 2004
51. Smith LT et al: Human dermatosparaxis: A form of Ehlers-Danlos syndrome that results from failure to remove the amino-terminal propeptide of type I procollagen. Am J Hum Genet 51(2):235-244, 1992
52. Petty EM et al: Dermatosparaxis in children. A case report and review of the newly recognized phenotype. Arch Dermatol 129(10):1310-1315, 1993
53. Fujimoto A, Wilcox WR, Cohn DH: Clinical, morphological, and biochemical phenotype of a new case of Ehlers-Danlos syndrome type VIIC. Am J Med Genet 68(1):25-28, 1997
54. Coman DJ: Diagnostic dilemma's: the congenital disorders of glycosylation are clinical chameleons. Eur J Hum Genet 16(1):2-4, 2008
55. Makareeva E et al: Molecular mechanism of alpha 1(I)-osteogenesis imperfecta/Ehlers-Danlos syndrome: Unfolding of an N-anchor domain at the N-terminal end of the type I
collagen triple helix.
J Biol Chem 28(10):6463-6470, 2006
56. Okajima T et al: Molecular basis for the progeroid variant of Ehlers-Danlos syndrome. Identification and characterization of two mutations in galactosyltransferase I gene. J Biol Chem 274(41):28841-28844, 1999
57. Sheen VL et al: Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome. Neurology 64(2):254-262, 2005
58. Kosho T et al: A new Ehlers-Danlos syndrome with craniofacial characteristics, multiple congenital contractures, progressive joint and skin laxity, and multisystem fragility-related manifestations. Am J Med Genet A 152A(6):1333-1346, 2010
59. Giunta C et al: Spondylocheiro dysplastic form of the Ehlers-Danlos syndrome–an autosomal-recessive entity caused by mutations in the zinc transporter gene SLC39A13. Am J Hum Genet 82(6):1290-1305, 2008
60. Loeys BL, Dietz HC: Loeys–Dietz syndrome. In: GeneReviews at GeneTests: Medical Genetics Information Resource. Seattle, University of Washington, 1993,
http://www.genetests.org61. Hoornaert KP et al: Stickler syndrome caused by COL2A1 mutations: Genotype-phenotype correlation in a series of 100 patients. Eur J Hum Genet 18(8):872-880, 2010
62. Rose PS et al: Stickler syndrome: Clinical characteristics and diagnostic criteria. Am J Med Genet A 138A(3):199-207, 2005
63. Morris CA, Mervis CB: Williams syndrome and related disorders. Annu Rev Genomics Hum Genet 1:461-484, 2000
64. Pasteris NG et al: Isolation and characterization of the faciogenital dysplasia (Aarskog-Scott syndrome) gene: A putative Rho/Rac guanine nucleotide exchange factor. Cell 79(4):669-678, 1994
65. Orrico A et al: Aarskog-Scott syndrome: Clinical update and report of nine novel mutations of the FGD1 gene. Am J Med Genet A 152A(2):313-318, 2010
66. Syx D et al: The RIN2 syndrome: A new autosomal recessive connective tissue disorder caused by deficiency of Ras and Rab interactor 2 (RIN2). Hum Genet 128(1):79-88, 2010
67. Basel-Vanagaite L et al: RIN2 deficiency results in macrocephaly, alopecia, cutis laxa, and scoliosis: MACS syndrome. Am J Hum Genet 85(2):254-263, 2009
68. Whitelaw SE: Ehlers-Danlos Syndrome, classical type: Case management. Pediatr Nurs 29(6):423-426, 2003
69. Whitelaw SE: Ehlers-Danlos syndrome, classical type: Case management. Dermatol Nurs 16(5):433-436, 449, 2004
71. Brooke BS et al: Contemporary management of vascular complications associated with Ehlers-Danlos syndrome. J Vasc Surg 51(1):131-138, 2010
72. Voermans NC et al: Fatigue is a frequent and clinically relevant problem in Ehlers-Danlos syndrome. Semin Arthritis Rheum 40(3):267-274, 2010
73. Voermans NC et al: Neuromuscular involvement in various types of Ehlers-Danlos syndrome. Ann Neurol 65(6):687-697, 2009
74. Pyeritz RE: The Marfan syndrome. Annu Rev Med 51:481-510, 2000
75. Rantamaki T et al: Recurrence of Marfan syndrome as a result of parental germ-line mosaicism for an FBN1 mutation. Am J Hum Genet 64(4):993-1001, 1999
76. Faivre L et al: Clinical and molecular study of 320 children with Marfan syndrome and related type I fibrillinopathies in a series of 1009 probands with pathogenic FBN1 mutations. Pediatrics 123(1):391-398, 2009
77. Pearson GD et al: Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders. Circulation 118(7):785-791, 2008
78. Lindeman JH et al: Distinct defects in
collagen microarchitecture underlie vessel-wall failure in advanced abdominal aneurysms and aneurysms in Marfan syndrome.
Proc Natl Acad Sci U S A 107(2):862-865, 2010
79. Dietz HC, Pyeritz RE: Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet 4(Spec No):1799-1809, 1995
80. Dietz HC et al: Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352(6333):337-339, 1991
81. Robinson PN et al: The molecular genetics of Marfan syndrome and related disorders. J Med Genet 43(10):769-787, 2006
82. Ramirez F: Fibrillln mutations in Marfan syndrome and related phenotypes. Curr Opin Genet Dev 6(3):309-315, 1996
83. Goumans MJ, Liu Z, ten DP: TGF-beta signaling in vascular biology and dysfunction. Cell Res 19(1):116-127, 2009
84. Jones JA, Ikonomidis JS: The pathogenesis of aortopathy in Marfan syndrome and related diseases. Curr Cardiol Rep 12(2):99-107, 2010
85. Rybczynski M et al: The spectrum of syndromes and manifestations in individuals screened for suspected Marfan syndrome. Am J Med Genet A 146A(24):3157-3166, 2008
86. Joseph KN et al: Orthopedic aspects of the Marfan phenotype. Clin Orthop Relat Res (277):251-261, 1992
87. Maumenee IH: The eye in the Marfan syndrome. Trans Am Ophthalmol Soc 79:684-733, 1981
88. Jeremy RW et al: Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. Am J Cardiol 74(4):369-373, 1994
89. Groenink M et al: Survival and complication free survival in Marfan's syndrome: Implications of current guidelines. Heart 82(4):499-504, 1999
90. Silverman DI et al: Life expectancy in the Marfan syndrome. Am J Cardiol 75(2):157-160, 1995
91. Seliem MA et al: Echocardiographic evaluation of the aortic root and mitral valve in children and adolescents with isolated pectus excavatum: Comparison with Marfan patients. Pediatr Cardiol 13(1):20-23, 1992
92. Ho NC, Tran JR, Bektas A: Marfan's syndrome. Lancet 366(9501):1978-1981, 2005
93. De PA et al: Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 62(4):417-426, 1996
94. Morse RP et al: Diagnosis and management of infantile marfan syndrome. Pediatrics 86(6):888-895, 1990
95. Buntinx IM et al: Neonatal Marfan syndrome with congenital arachnodactyly, flexion contractures, and severe cardiac valve insufficiency. J Med Genet 28(4):267-273, 1991
96. Gupta PA et al: Ten novel FBN2 mutations in congenital contractural arachnodactyly: Delineation of the molecular pathogenesis and clinical phenotype. Hum Mutat 19(1):39-48, 2002
97. Callewaert BL et al: Comprehensive clinical and molecular assessment of 32 probands with congenital contractural arachnodactyly: Report of 14 novel mutations and review of the literature. Hum Mutat 30(3):334-341, 2009
99. Arn PH et al: Outcome of pectus excavatum in patients with Marfan syndrome and in the general population. J Pediatr 115(6):954-958, 1989
100. Shores J et al: Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 330(19):1335-1341, 1994
101. Gray JR et al: Life expectancy in British Marfan syndrome populations. Clin Genet 54(2):124-128, 1998
102. Brooke BS et al: Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 358(26):2787-2795, 2008
103. Hall JR et al: Pneumothorax in the Marfan syndrome: Prevalence and therapy. Ann Thorac Surg 37(6):500-504, 1984
104. Yap S: Classical homocystinuria: Vascular risk and its prevention. J Inherit Metab Dis 26(2-3):259-265, 2003
105. Naughten ER, Yap S, Mayne PD: Newborn screening for homocystinuria: Irish and world experience. Eur J Pediatr 157(Suppl. 2):S84-S87, 1998
106. Skovby F, Gaustadnes M, Mudd SH: A revisit to the natural history of homocystinuria due to cystathionine beta-synthase deficiency. Mol Genet Metab 99(1):1-3, 2010
107. Munke M et al: The gene for cystathionine beta-synthase (CBS) maps to the subtelomeric region on human chromosome 21q and to proximal mouse chromosome 17. Am J Hum Genet 42(4):550-559, 1988
108. Miles EW, Kraus JP: Cystathionine beta-synthase: Structure, function, regulation, and location of homocystinuria-causing mutations. J Biol Chem 279(29):29871-29874, 2004
109. Kraus JP et al: Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat 13(5):362-375, 1999
110. Urreizti R et al: The p.T191M mutation of the CBS gene is highly prevalent among homocystinuric patients from Spain, Portugal and South America. J Hum Genet 51(4):305-313, 2006
111. Hu FL et al: Molecular basis of cystathionine beta-synthase deficiency in
pyridoxine responsive and nonresponsive homocystinuria.
Hum Mol Genet 2(11):1857-1860, 1993
112. Gallagher PM et al: High frequency (71%) of cystathionine beta-synthase mutation G307S in Irish homocystinuria patients. Hum Mutat 6(2):177-180, 1995
113. Hubmacher D et al: Functional consequences of homocysteinylation of the elastic fiber proteins fibrillin-1 and tropoelastin. J Biol Chem 285(2):1188-1198, 2010
114. de Franchis R et al: Clinical aspects of cystathionine beta-synthase deficiency: How wide is the spectrum? The Italian Collaborative Study Group on Homocystinuria. Eur J Pediatr 157(Suppl. 2):S67-S70, 1998
115. Mudd SH et al: The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 37(1):1-31, 1985
116. Tan WH et al: Isolated sulfite oxidase deficiency: A case report with a novel mutation and review of the literature. Pediatrics 116(3):757-766, 2005
117. Lerner-Ellis JP et al: Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. Nat Genet 38(1):93-100, 2006
118. Morel CF, Lerner-Ellis JP, Rosenblatt DS: Combined methylmalonic aciduria and homocystinuria (cblC): Phenotype-genotype correlations and ethnic-specific observations. Mol Genet Metab 88(4):315-321, 2006
119. Picker JD, Levy HL: Homocystinuria caused by cystathionine beta-synthase deficiency. In: GeneReviews at GeneTests: Medical Genetics Information Resource. Seattle, University of Washington, 1993,
http://www.genetests.org120. Chen X et al: Contrasting behaviors of mutant cystathionine beta-synthase enzymes associated with
pyridoxine response.
Hum Mutat 27(5):474-482, 2006
121. Lawson-Yuen A, Levy HL: The use of
betaine in the treatment of elevated homocysteine.
Mol Genet Metab 88(3):201-207, 2006
122. Yaghmai R et al: Progressive cerebral edema associated with high methionine levels and
betaine therapy in a patient with cystathionine beta-synthase (CBS) deficiency.
Am J Med Genet 108(1):57-63, 2002
123. Martin L et al: Heterozygosity for a single mutation in the ABCC6 gene may closely mimic PXE: Consequences of this phenotype overlap for the definition of PXE. Arch Dermatol 144(3):301-306, 2008
124. Uitto J, Jiang Q: Pseudoxanthoma elasticum-like phenotypes: More diseases than one. J Invest Dermatol 127(3):507-510, 2007
125. Jiang Q et al: Pseudoxanthoma elasticum is a metabolic disease. J Invest Dermatol 129(2):348-354, 2009
126. Li Q et al: Pseudoxanthoma elasticum: Clinical phenotypes, molecular genetics and putative pathomechanisms. Exp Dermatol 18(1):1-11, 2009
127. Le SO et al: Evidence for a founder effect for pseudoxanthoma elasticum in the Afrikaner population of South Africa. Hum Genet 111(4-5):331-338, 2002
128. Jiang Q et al: Parabiotic heterogenetic pairing of Abcc6-/-/Rag1-/- mice and their wild-type counterparts halts ectopic mineralization in a murine model of pseudoxanthoma elasticum. Am J Pathol 176(4):1855-1862, 2010
129. Vanakker OM et al: Low serum vitamin K in PXE results in defective carboxylation of mineralization inhibitors similar to the GGCX mutations in the PXE-like syndrome. Lab Invest 90(6):895-905, 2010
130. Lebwohl M et al: Classification of pseudoxanthoma elasticum: Report of a consensus conference. J Am Acad Dermatol 30(1):103-107, 1994
131. Kazakis AM, Parish WR: Periumbilical perforating pseudoxanthoma elasticum. J Am Acad Dermatol 19(2 Pt 2):384-388, 1988
132. Lebwohl M et al: Diagnosis of pseudoxanthoma elasticum by scar biopsy in patients without characteristic skin lesions. N Engl J Med 317(6):347-350, 1987
133. Hellemans J et al: Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet 36(11):1213-1218, 2004
134. Neldner KH, Martinez-Hernandez A: Localized acquired cutaneous pseudoxanthoma elasticum. J Am Acad Dermatol 1(6):523-530, 1979
135. Karp DL et al: A yellow plaque with keratotic papules on the abdomen. Perforating calcific elastosis (periumbilical perforating pseudoxanthoma elasticum [PXE], localized acquired cutaneous PXE). Arch Dermatol 132(2):224-228, 1996
136. Becuwe C et al: Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with
penicillamine.
Dermatology 210(1):60-63, 2005
137. Lewis KG et al: Acquired disorders of elastic tissue: Part II. decreased elastic tissue. J Am Acad Dermatol 51(2):165-185, 2004
138. Li TH et al: An unusual cutaneous manifestation of pseudoxanthoma elasticum mimicking reticulate pigmentary disorders. Br J Dermatol 134(6):1157-1159, 1996
139. Viljoen DL et al: Pseudoxanthoma elasticum in South Africa–genetic and clinical implications. S Afr Med J 66(21):813-816, 1984
140. Naouri M et al: Manifestations of pseudoxanthoma elasticum in childhood. Br J Dermatol 161(3):635-639, 2009
141. Georgalas I et al: Angioid streaks, clinical course, complications, and current therapeutic management. Ther Clin Risk Manag 5(1):81-89, 2009
142. Nishida H et al: Coronary artery bypass in a 15-year-old girl with pseudoxanthoma elasticum. Ann Thorac Surg 49(3):483-485, 1990
143. Viljoen DL, Beatty S, Beighton P: The obstetric and gynaecological implications of pseudoxanthoma elasticum. Br J Obstet Gynaecol 94(9):884-888, 1987
144. Bowen AR et al: Pseudoxanthoma elasticum-like fibers in the inflamed skin of patients without pseudoxanthoma elasticum. J Cutan Pathol 34(10):777-781, 2007
145. Hacker SM et al: Juvenile pseudoxanthoma elasticum: Recognition and management. Pediatr Dermatol 10(1):19-25, 1993
146. Suarez MJ et al: Sonographic aspects of pseudoxanthoma elasticum. Pediatr Radiol 21(7):538-539, 1991
147. Aessopos A, Farmakis D, Loukopoulos D: Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. Blood 99(1):30-35, 2002
148. Coatesworth AP et al: A case of systemic pseudo-pseudoxanthoma elasticum with diverse symptomatology caused by long-term
penicillamine use.
J Clin Pathol 51(2):169-171, 1998
149. Lewis KG et al: Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum-like changes. J Cutan Pathol 33(10):695-700, 2006
150. Farmakis D et al: Aortic valve replacement in a patient with thalassemia intermedia. Ann Thorac Surg 81(2):737-739, 2006
151. Laube S, Moss C: Pseudoxanthoma elasticum. Arch Dis Child 90(7):754-756, 2005
152. Viljoen DL, Bloch C, Beighton P: Plastic surgery in pseudoxanthoma elasticum: Experience in nine patients. Plast Reconstr Surg 85(2):233-238, 1990
153. Cunningham JR et al: Pseudoxanthoma elasticum: Treatment of gastrointestinal hemorrhage by arterial embolization and observations on autosomal dominant inheritance. Johns Hopkins Med J 147(4):168-173, 1980
154. Browning
AC et al:
Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: One-year results of a prospective case series.
Ophthalmology 112(7):1227-1231, 2005
155. Lommatzsch A: Management of choroidal vascularisation. Br J Ophthalmol 92(4):445-446, 2008
156. Hamamoto Y et al: Hyperreactivity of pseudoxanthoma elasticum-affected dermis to vitamin D3. J Am Acad Dermatol 42(4):685-687, 2000
157. Sherer DW et al: Oral phosphate binders in the treatment of pseudoxanthoma elasticum. J Am Acad Dermatol 53(4):610-615, 2005
158. Takata T et al: Treatment of pseudoxanthoma elasticum with tocopherol acetate and ascorbic acid. Pediatr Dermatol 24(4):424-425, 2007
159. Li Q et al: Magnesium carbonate-containing phosphate binder prevents connective tissue mineralization in Abcc6(-/-) mice-potential for treatment of pseudoxanthoma elasticum. Clin Transl Sci 2(6):398-404, 2009
160. LaRusso J et al: Elevated dietary magnesium prevents connective tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6(-/-)). J Invest Dermatol 129(6):1388-1394, 2009
161. Graul-Neumann LM et al: Highly variable cutis laxa resulting from a dominant splicing mutation of the elastin gene. Am J Med Genet A 146A(8):977-983, 2008
162. Urban Z et al: Autosomal dominant cutis laxa with severe lung disease: Synthesis and matrix deposition of mutant tropoelastin. J Invest Dermatol 124(6):1193-1199, 2005
163. Beighton P: The dominant and recessive forms of cutis laxa. J Med Genet 9(2):216-221, 1972
164. Damkier A, Brandrup F, Starklint H: Cutis laxa: Autosomal dominant inheritance in five generations. Clin Genet 39(5):321-329, 1991
165. Markova D et al: Genetic heterogeneity of cutis laxa: A heterozygous tandem duplication within the fibulin-5 (FBLN5) gene. Am J Hum Genet 72(4):998-1004, 2003
166. Kielty CM: Elastic fibres in health and disease. Expert Rev Mol Med 8(19):1-23, 2006
167. Morava E et al: Autosomal recessive cutis laxa syndrome revisited. Eur J Hum Genet 17(9):1099-1110, 2009
168. Ringpfeil F: Selected disorders of connective tissue: Pseudoxanthoma elasticum, cutis laxa, and lipoid proteinosis. Clin Dermatol 23(1):41-46, 2005
169. Hu Q et al: Fibulin-5 mutations: Mechanisms of impaired elastic fiber formation in recessive cutis laxa. Hum Mol Genet 15(23):3379-3386, 2006
170. Hucthagowder V et al: Fibulin-4: A novel gene for an autosomal recessive cutis laxa syndrome. Am J Hum Genet 78(6):1075-1080, 2006
171. Reversade B et al: Mutations in PYCR1 cause cutis laxa with progeroid features. Nat Genet 41(9):1016-1021, 2009
172. Morava E et al: Defining the phenotype in an autosomal recessive cutis laxa syndrome with a combined congenital defect of glycosylation. Eur J Hum Genet 16(1):28-35, 2008
173. Kornak U et al: Impaired glycosylation and cutis laxa caused by mutations in the vesicular H+-ATPase subunit ATP6V0A2. Nat Genet 40(1):32-34, 2008
174. Hennies HC et al: Gerodermia osteodysplastica is caused by mutations in SCYL1BP1, a Rab-6 interacting golgin. Nat Genet 40(12):1410-1412, 2008
175. Kivuva
EC et al: De Barsy syndrome: A review of the phenotype.
Clin Dysmorphol 17(2):99-107, 2008
176. Gupta N, Phadke SR: Cutis laxa type II and wrinkly skin syndrome: Distinct phenotypes. Pediatr Dermatol 23(3):225-230, 2006
177. Urban Z et al: Mutations in LTBP4 cause a syndrome of impaired pulmonary, gastrointestinal, genitourinary, musculoskeletal, and dermal development. Am J Hum Genet 85(5):593-605, 2009
178. Valayannopoulos V et al: Transaldolase deficiency: A new cause of hydrops fetalis and neonatal multi-organ disease. J Pediatr 149(5):713-717, 2006
179. Bouloc A et al: Increased fibroblast elastase activity in acquired cutis laxa. Dermatology 198(4):346-350, 1999
180. Hu Q et al: Inflammatory destruction of elastic fibers in acquired cutis laxa is associated with missense alleles in the elastin and fibulin-5 genes. J Invest Dermatol 126(2):283-290, 2006
181. Uenishi T et al: Pseudoxanthoma elasticum with generalized cutaneous laxity. Arch Dermatol 133(5):664-666, 1997
182. Vanakker OM et al: Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity. J Invest Dermatol 127(3):581-587, 2007
183. Bangsgaard N et al: Nephrogenic systemic fibrosis: Late skin manifestations. Arch Dermatol 145(2):183-187, 2009
184. Haider M et al: Acquired cutis laxa type II (Marshall syndrome) in an 18-month-old child: A case report. Pediatr Dermatol 27(1):89-91, 2010
185. Muster AJ et al: Fatal cardiovascular disease and cutis laxa following acute febrile neutrophilic dermatosis. J Pediatr 102(2):243-248, 1983
186. Hill
VA, Seymour CA, Mortimer PS: Pencillamine-induced elastosis perforans serpiginosa and cutis laxa in Wilson's disease.
Br J Dermatol 142(3):560-561, 2000
187. Mahajan VK, Sharma NL, Garg G: Cutis laxa acquisita associated with cutaneous mastocytosis. Int J Dermatol 45(8):949-951, 2006
188. Kiuru-Enari S, Keski-Oja J, Haltia M: Cutis laxa in hereditary gelsolin amyloidosis. Br J Dermatol 152(2):250-257, 2005
189. Linares A et al: Reversible cutis laxa due to maternal D-penicillamine treatment. Lancet 2(8132):43, 1979
190. Solomon L et al: Neonatal abnormalities associated with D-penicillamine treatment during pregnancy. N Engl J Med 296(1):54-55, 1977
191. Nahas FX et al: The role of plastic surgery in congenital cutis laxa: A 10-year follow-up. Plast Reconstr Surg 104(4):1174-1178, 1999
192. Fisher BK, Page E, Hanna W: Acral localized acquired cutis laxa. J Am Acad Dermatol 21(1):33-40, 1989
193. Tamura BM et al: Cutis laxa: Improvement of facial aesthetics by using botulinum toxin. Dermatol Surg 30(12 Pt 2):1518-1520, 2004
194. Hirano E et al: Functional rescue of elastin insufficiency in mice by the human elastin gene: Implications for mouse models of human disease. Circ Res 101(5):523-531, 2007
195. Steiner RD, Pepin MG, Byers PH: Osteogenesis imperfecta. In: GeneReviews at GeneTests: Medical Genetics Information Resource. Seattle, University of Washington, 1993,
http://www.genetests.org196. Tinkle BT, Wenstrup RJ: A genetic approach to fracture epidemiology in childhood. Am J Med Genet C Semin Med Genet 139C(1):38-54, 2005
197. Stevenson CJ, Bottoms E, Shuster S: Skin
collagen in osteogenesis imperfecta.
Lancet 1(7652):860-861, 1970
198. Prockop DJ: Osteogenesis imperfecta: Phenotypic heterogeneity, protein suicide, short and long
collagen.
Am J Hum Genet 36(3):499-505, 1984
199. Hansen B, Jemec GB: The mechanical properties of skin in osteogenesis imperfecta. Arch Dermatol 138(7):909-911, 2002
200. Barnes AM et al: Lack of cyclophilin B in osteogenesis imperfecta with normal
collagen folding.
N Engl J Med 362(6):521-528, 2010
201. Alanay Y et al: Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 86(4):551-559, 2010
202. Gahagan S, Rimsza ME: Child abuse or osteogenesis imperfecta: How can we tell? Pediatrics 88(5):987-992, 1991
203. Glorieux FH: Osteogenesis imperfecta. Best Pract Res Clin Rheumatol 22(1):85-100, 2008
204. Marini JC et al: The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. J Clin Endocrinol Metab 76(1):251-256, 1993
205. Cheung MS, Glorieux FH: Osteogenesis Imperfecta: Update on presentation and management. Rev Endocr Metab Disord 9(2):153-160, 2008
206. Le BK et al: Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 79(11):1607-1614, 2005
207. Gass JK et al: Buschke-Ollendorff syndrome: A manifestation of a heterozygous nonsense mutation in the LEMD3 gene. J Am Acad Dermatol 58(5 Suppl. 1):S103-S104, 2008
208. Schena D et al: Buschke-Ollendorff syndrome. Int J Dermatol 47(11):1159-1161, 2008
209. Hellemans J et al: Germline LEMD3 mutations are rare in sporadic patients with isolated melorheostosis. Hum Mutat 27(3):290, 2006
210. Van Hougenhouck-Tulleken W et al: Clinical and molecular characterization of lipoid proteinosis in Namaqualand, South Africa. Br J Dermatol 151(2):413-423, 2004
211. Hamada T et al: Extracellular matrix protein 1 gene (ECM1) mutations in lipoid proteinosis and genotype-phenotype correlation. J Invest Dermatol 120(3):345-350, 2003
212. Sercu S et al: ECM1 interacts with fibulin-3 and the beta 3 chain of laminin 332 through its serum
albumin subdomain-like 2 domain.
Matrix Biol 28(3):160-169, 2009
213. Fujimoto N et al: Extracellular matrix protein 1 interacts with the domain III of fibulin-1C and 1D variants through its central tandem repeat 2. Biochem Biophys Res Commun 333(4):1327-1333, 2005
214. Dyer JA, Yu QC, Paller AS: “Free-floating” desmosomes in lipoid proteinosis: An inherent defect in keratinocyte adhesion? Pediatr Dermatol 23(1):1-6, 2006
215. Sercu S et al: Functional redundancy of extracellular matrix protein 1 in epidermal differentiation. Br J Dermatol 157(4):771-775, 2007
216. Chan I: The role of extracellular matrix protein 1 in human skin. Clin Exp Dermatol 29(1):52-56, 2004
217. Kowalewski C et al: Three-dimensional imaging reveals major changes in skin microvasculature in lipoid proteinosis and lichen sclerosus. J Dermatol Sci 38(3):215-224, 2005
218. Oyama N et al: Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet 362(9378):118-123, 2003
219. Hamada T: Lipoid proteinosis. Clin Exp Dermatol 27(8):624-629, 2002
220. Sargenti NS, Batista JD, Durighetto AJ: A case of oral recurrent ulcerative lesions in a patient with lipoid proteinosis (Urbach-Wiethe disease). Br J Oral Maxillofac Surg 48(8):654-655, 2009
221. Cote DN: Head and neck manifestations of lipoid proteinosis. Otolaryngol Head Neck Surg 119(1):144-145, 1998
222. Siebert M, Markowitsch HJ, Bartel P: Amygdala, affect and cognition: Evidence from 10 patients with Urbach-Wiethe disease. Brain 126(Pt 12):2627-2637, 2003
223. Paller AS: Histology of lipoid proteinosis. JAMA 272(7):564-565, 1994
224. Ko C, Barr RJ: Vesicular lesions in a patient with lipoid proteinosis: A probable acantholytic dermatosis. Am J Dermatopathol 25(4):335-337, 2003
225. Teive HA et al: Generalized dystonia and striatal calcifications with lipoid proteinosis. Neurology 63(11):2168-2169, 2004
226. Chan I et al: Rapid diagnosis of lipoid proteinosis using an anti-extracellular matrix protein 1 (ECM1) antibody. J Dermatol Sci 35(2):151-153, 2004
227. Ozkaya-Bayazit E et al: [Oral DMSO therapy in 3 patients with lipoidproteinosis. Results of long-term therapy]. Hautarzt 48(7):477-481, 1997
228. Toosi S, Ehsani AH: Treatment of lipoid proteinosis with
acitretin: A case report.
J Eur Acad Dermatol Venereol 23(4):482-483, 2009
229. Haneke E et al: Hyalinosis cutis et mucosae in siblings. Hum Genet 68(4):342-345, 1984
230. Rosenthal G et al: Carbon dioxide laser treatment for lipoid proteinosis (Urbach-Wiethe syndrome) involving the eyelids. Br J Ophthalmol 81(3):253, 1997